MA43409B1 - Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton - Google Patents
Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de brutonInfo
- Publication number
- MA43409B1 MA43409B1 MA43409A MA43409A MA43409B1 MA 43409 B1 MA43409 B1 MA 43409B1 MA 43409 A MA43409 A MA 43409A MA 43409 A MA43409 A MA 43409A MA 43409 B1 MA43409 B1 MA 43409B1
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitors
- tyrosine kinase
- polycyclic compounds
- bruton tyrosine
- compounds
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 125000003367 polycyclic group Chemical group 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265836P | 2015-12-10 | 2015-12-10 | |
| PCT/US2016/065954 WO2017100662A1 (en) | 2015-12-10 | 2016-12-09 | Polycyclic compounds as inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43409B1 true MA43409B1 (fr) | 2020-10-28 |
Family
ID=57681784
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43409A MA43409B1 (fr) | 2015-12-10 | 2016-12-09 | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton |
| MA053110A MA53110A (fr) | 2015-12-10 | 2016-12-09 | Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053110A MA53110A (fr) | 2015-12-10 | 2016-12-09 | Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10717745B2 (enExample) |
| EP (2) | EP3386991B1 (enExample) |
| JP (2) | JP6835846B2 (enExample) |
| KR (1) | KR102103395B1 (enExample) |
| CN (2) | CN113121562B (enExample) |
| AR (1) | AR107042A1 (enExample) |
| AU (1) | AU2016366541B2 (enExample) |
| BR (1) | BR112018011526B1 (enExample) |
| CA (1) | CA3007990C (enExample) |
| CY (1) | CY1123263T1 (enExample) |
| DK (1) | DK3386991T3 (enExample) |
| EA (1) | EA035168B1 (enExample) |
| ES (1) | ES2805835T3 (enExample) |
| HR (1) | HRP20201193T1 (enExample) |
| HU (1) | HUE049502T2 (enExample) |
| IL (1) | IL259863B (enExample) |
| JO (1) | JO3794B1 (enExample) |
| LT (1) | LT3386991T (enExample) |
| MA (2) | MA43409B1 (enExample) |
| MD (1) | MD3386991T2 (enExample) |
| ME (1) | ME03803B (enExample) |
| MX (1) | MX387590B (enExample) |
| PL (1) | PL3386991T3 (enExample) |
| PT (1) | PT3386991T (enExample) |
| RS (1) | RS60604B1 (enExample) |
| SI (1) | SI3386991T1 (enExample) |
| SM (1) | SMT202000404T1 (enExample) |
| TW (1) | TWI729047B (enExample) |
| UY (1) | UY37015A (enExample) |
| WO (1) | WO2017100662A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2018170220A1 (en) * | 2017-03-15 | 2018-09-20 | Janssen Sciences Ireland Uc | Methods of selective aryl- and heteroaryl-nitrogen bond formation |
| CN108164397B (zh) * | 2018-01-18 | 2020-11-13 | 暨南大学 | 一类邻苯二酚衍生物及其制备方法 |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| KR20210151880A (ko) | 2019-04-11 | 2021-12-14 | 얀센 파마슈티카 엔.브이. | Malt1 억제제로서의 피리딘 고리 함유 유도체 |
| US20230094146A1 (en) * | 2020-01-07 | 2023-03-30 | Medshine Discovery Inc. | Deuterated thienopyridine compound |
| JP2024509828A (ja) * | 2021-03-03 | 2024-03-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤及びｂｔｋ阻害剤を使用する併用療法 |
| IL308951A (en) | 2021-06-04 | 2024-01-01 | Janssen Pharmaceutica Nv | Inhibitors of proton tyrosine kinase and methods of using them |
| CA3223610A1 (en) | 2021-06-30 | 2023-01-05 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| MX2024001840A (es) | 2021-08-09 | 2024-02-28 | Janssen Pharmaceutica Nv | Composiciones para usar en el tratamiento de neoplasias de celulas b. |
| EP4479405A1 (en) * | 2022-02-18 | 2024-12-25 | JANSSEN Pharmaceutica NV | Synthesis of bruton's tyrosine kinase inhibitors |
| WO2025262118A1 (en) | 2024-06-20 | 2025-12-26 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3112415A1 (de) | 1981-03-28 | 1982-10-07 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden |
| US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| CN101056639A (zh) | 2004-09-15 | 2007-10-17 | 詹森药业有限公司 | 噻唑并吡啶激酶抑制剂 |
| WO2006118749A1 (en) * | 2005-05-04 | 2006-11-09 | Janssen Pharmaceutica, N.V. | Thia-tetraazaacenaphthylene kinase inhibitors |
| AU2006278627B2 (en) | 2005-08-08 | 2011-08-18 | Janssen Pharmaceutica, N.V. | Thiazolopyrimidine kinase inhibitors |
| WO2007092879A2 (en) * | 2006-02-08 | 2007-08-16 | Janssen Pharmaceutica, N.V. | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors |
| ES2673973T3 (es) | 2006-09-22 | 2018-06-26 | Pharmacyclics Llc | Inhibidores de tirosina cinasa de Bruton |
| WO2010056875A1 (en) * | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| US8486965B2 (en) | 2009-08-26 | 2013-07-16 | Takeda Pharmaceutical Company Limited | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer |
| US9371567B2 (en) | 2010-04-19 | 2016-06-21 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of BTK inhibitors |
| FR2978441A1 (fr) | 2011-07-25 | 2013-02-01 | Diverchim | Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques |
| SI2970291T1 (sl) | 2013-03-15 | 2022-07-29 | Janssen Pharmaceutica, N.V. | Postopki in vmesne spojine za pripravo zdravila |
| EA030538B1 (ru) * | 2013-12-11 | 2018-08-31 | Байоджен Ма Инк. | Биарильное соединение, применяемое при лечении заболеваний человека в онкологии, неврологии и иммунологии |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| WO2018103058A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2016
- 2016-12-08 JO JOP/2016/0256A patent/JO3794B1/ar active
- 2016-12-09 CN CN202110404024.3A patent/CN113121562B/zh active Active
- 2016-12-09 DK DK16820106.9T patent/DK3386991T3/da active
- 2016-12-09 WO PCT/US2016/065954 patent/WO2017100662A1/en not_active Ceased
- 2016-12-09 RS RS20200884A patent/RS60604B1/sr unknown
- 2016-12-09 ES ES16820106T patent/ES2805835T3/es active Active
- 2016-12-09 HR HRP20201193TT patent/HRP20201193T1/hr unknown
- 2016-12-09 EP EP16820106.9A patent/EP3386991B1/en active Active
- 2016-12-09 PT PT168201069T patent/PT3386991T/pt unknown
- 2016-12-09 SM SM20200404T patent/SMT202000404T1/it unknown
- 2016-12-09 EA EA201891378A patent/EA035168B1/ru unknown
- 2016-12-09 SI SI201630825T patent/SI3386991T1/sl unknown
- 2016-12-09 MX MX2018007075A patent/MX387590B/es unknown
- 2016-12-09 UY UY0001037015A patent/UY37015A/es active IP Right Grant
- 2016-12-09 CN CN201680072125.2A patent/CN108884106A/zh active Pending
- 2016-12-09 US US15/374,905 patent/US10717745B2/en active Active
- 2016-12-09 PL PL16820106T patent/PL3386991T3/pl unknown
- 2016-12-09 MD MDE20180978T patent/MD3386991T2/ro unknown
- 2016-12-09 HU HUE16820106A patent/HUE049502T2/hu unknown
- 2016-12-09 LT LTEP16820106.9T patent/LT3386991T/lt unknown
- 2016-12-09 BR BR112018011526-6A patent/BR112018011526B1/pt active IP Right Grant
- 2016-12-09 AU AU2016366541A patent/AU2016366541B2/en active Active
- 2016-12-09 ME MEP-2020-155A patent/ME03803B/me unknown
- 2016-12-09 TW TW105140760A patent/TWI729047B/zh active
- 2016-12-09 KR KR1020187018900A patent/KR102103395B1/ko active Active
- 2016-12-09 JP JP2018530000A patent/JP6835846B2/ja active Active
- 2016-12-09 CA CA3007990A patent/CA3007990C/en active Active
- 2016-12-09 MA MA43409A patent/MA43409B1/fr unknown
- 2016-12-09 EP EP20177012.0A patent/EP3719022A1/en active Pending
- 2016-12-09 MA MA053110A patent/MA53110A/fr unknown
- 2016-12-12 AR ARP160103789A patent/AR107042A1/es active IP Right Grant
-
2018
- 2018-06-07 IL IL259863A patent/IL259863B/en active IP Right Grant
-
2019
- 2019-05-15 US US16/413,453 patent/US10934310B2/en active Active
-
2020
- 2020-05-13 US US15/931,437 patent/US11319329B2/en active Active
- 2020-08-18 CY CY20201100769T patent/CY1123263T1/el unknown
-
2021
- 2021-02-04 JP JP2021016602A patent/JP7072690B2/ja active Active
-
2022
- 2022-03-25 US US17/705,225 patent/US12065446B2/en active Active
-
2024
- 2024-07-03 US US18/763,484 patent/US20240383914A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MX2019003618A (es) | Inhibidores de pirimidinil tirosina cinasa. | |
| MA37959A2 (fr) | Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
| MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
| MA39317A1 (fr) | Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| ZA202001780B (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
| MA38884A1 (fr) | Composé de triazolopyridine, compositions et procédés d'utilisation associés | |
| MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
| JO3793B1 (ar) | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| MX2019000884A (es) | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| FR3078704B1 (fr) | Derives d'isohexide et leurs utilisations | |
| MA45609B1 (fr) | Compositions d'acide cromoglicique pour le traitement de la dermatite | |
| MA38523A1 (fr) | Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma | |
| MA54520B1 (fr) | Composés anticancéreux | |
| EA201992728A1 (ru) | Ингибиторы киназы и способы их применения | |
| FR3022245B1 (fr) | Derives de 3,5-dihydro-2h-pyrazolo[4,3-c]pyridin-3-one et leur utilisation |